Results 61 to 70 of about 70,073 (274)

Darolutamide For Castration-Resistant Prostate Cancer.

OncoTargets and therapy, 2019
The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone ...
Bastos,Diogo A, Antonarakis,Emmanuel S
openaire   +3 more sources

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications

Therapeutic Advances in Medical Oncology, 2017
Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy.
Naoki Terada, Shusuke Akamatsu, Takashi Kobayashi, Takahiro Inoue, Osamu Ogawa, Emmanuel S Antonarakis   +5 more
doaj   +1 more source

Castration-resistant prostate cancer: systemic therapy in 2012

Clinics, 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease
Fernando C. Maluf, Oren Smaletz, Daniel Herchenhorn   +2 more
doaj   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology, 2019
Summary Background Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in ...
J. Mateo, N. Porta, D. Bianchini, U. McGovern, T. Elliott, Robert J. Jones, I. Syndikus, C. Ralph, Suneil Jain, M. Varughese, O. Parikh, S. Crabb, A. Robinson, D. McLaren, A. Birtle, J. Tanguay, S. Miranda, I. Figueiredo, G. Seed, C. Bertan, P. Flohr, Berni Ebbs, P. Rescigno, Gemma Fowler, A. Ferreira, R. Riisnaes, Rita Pereira, A. Curcean, R. Chandler, M. Clarke, B. Gurel, M. Crespo, Daniel Nava Rodrigues, S. Sandhu, A. Espinasse, P. Chatfield, N. Tunariu, W. Yuan, E. Hall, S. Carreira, J. D. de Bono   +40 more
semanticscholar   +1 more source

PVT1 lincRNA signals an androgen‐dependent transcriptional activation program of oncogenes in prostate cancer cells

International Journal of Cancer, EarlyView.
What's New? Unraveling the networks that regulate androgen receptor (AR) function is critical to better understanding prostate cancer development and progression. Of particular interest in this regard is the long non‐coding RNA PVT1, which regulates gene expression in cancer and is upregulated in prostate tumors.
Maria Gabriela Berzoti‐Coelho, Fabio Nunes de Mello, Ana Carolina Tahira, Gabriel Nakanishi Fortes, Agatha Fischer‐Carvalho, Pedro Jardim Poli, Murilo Sena Amaral, Sergio Verjovski‐Almeida   +7 more
wiley   +1 more source

Current Management of Castrate-Resistant Prostate Cancer

Current Oncology, 2010
Prostate cancer (PCa) is the most frequently diagnosed cancer in North America. Castrate-resistant PCa presents a spectrum of disease ranging from rising PSA levels in the absence of metastases or symptoms and despite androgen-deprivation therapy, to metastases and significant debilitation from cancer symptoms.
Hotte, S.J., Saad, F.
openaire   +2 more sources

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

Journal of Clinical Oncology, 2019
PURPOSE Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)-positive metastatic castration-resistant prostate cancer (mCRPC).
E. Antonarakis, J. Piulats, M. Gross-Goupil, J. Goh, K. Ojamaa, C. Hoimes, U. Vaishampayan, R. Berger, A. Sezer, T. Alanko, R. de Wit, Chunde Li, A. Omlin, G. Procopio, S. Fukasawa, K. Tabata, S. Park, S. Feyerabend, C. Drake, Haiyan Wu, P. Qiu, Jeri Kim, C. Poehlein, J. D. de Bono   +23 more
semanticscholar   +1 more source

Organoids and organ‐on‐a‐chip models for investigating the pathophysiology of the human reproductive system

Interdisciplinary Medicine, EarlyView.
Organoids and organ‐on‐a‐chips are advancing reproductive system research. In the female reproductive system, applications include cancer organoid models, placental chips, and hormone simulation models. For the male reproductive system, research focuses on drug resistance mechanisms, co‐culture platforms, and infertility studies. These refined in vitro
Hongqi Zhang, Shiwen Deng, Fangfang Jin, Jiayao Qu, Xiang Fan, Peng Chen, Xinrong Fan   +6 more
wiley   +1 more source